Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCP1201 vs Metformin and Rosuvastatin PK Study
NCT02026817Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Dec 2013
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rosuvastatin + metformin in type 2 diabetes mellitus (T2DM) and hypercholesterolemia (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at 48 hours and Area Under the Curve to the Last Measurable Concentration at 48 hours. Started Dec 2013; status: completed.
02
Drugs
rosuvastatin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)hypercholesterolemia
Beyond the preview
Go deeper on NCT02026817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02026817.